Travere Therapeutics Inc [TVTX] stock prices are saw in change for the day to $19.46 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The TVTX shares have gain 14.00% over the last week, with a monthly amount glided 15.42%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wells Fargo upgraded its rating to Overweight on October 21, 2024, and elevated its price target to $27. On October 16, 2024, Scotiabank initiated with a Sector Outperform rating. Guggenheim upgraded its rating to a Buy but stick to its price target of $25 on September 09, 2024. Guggenheim downgraded its rating to a Neutral. Citigroup upgraded its rating to Buy for this stock on December 05, 2023, and upped its price target to $10. In a note dated November 20, 2023, Citigroup initiated an Neutral rating and provided a target price of $7 on this stock.
The stock price of Travere Therapeutics Inc [TVTX] has been fluctuating between $5.12 and $20.33 over the past year. Currently, Wall Street analysts expect the stock to reach $21.75 within the next 12 months. Travere Therapeutics Inc [NASDAQ: TVTX] shares were valued at $19.46 at the most recent close of the market. An investor can expect a potential return of 11.77% based on the average TVTX price forecast.
Analyzing the TVTX fundamentals
The Travere Therapeutics Inc [NASDAQ:TVTX] reported sales of 203.45M for trailing twelve months, representing a surge of 69.56%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -1.69%, Pretax Profit Margin comes in at -1.71%, and Net Profit Margin reading is -1.73%. To continue investigating profitability, this company’s Return on Assets is posted at -0.7, Equity is -5.42 and Total Capital is -1.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -13.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.76 points at the first support level, and at 18.07 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.92, and for the 2nd resistance point, it is at 20.39.
Ratios To Look Out For
It’s worth pointing out that Travere Therapeutics Inc [NASDAQ:TVTX]’s Current Ratio is 1.71. On the other hand, the Quick Ratio is 1.68, and the Cash Ratio is 0.19. Considering the valuation of this stock, the price to sales ratio is 8.32.
Transactions by insiders
Recent insider trading involved Dube Eric M, Officer, that happened on Jan 22 ’25 when 10736.0 shares were purchased. Officer, REED ELIZABETH E completed a deal on Jan 22 ’25 to buy 2437.0 shares. Meanwhile, Officer ROTE WILLIAM E. bought 2437.0 shares on Jan 22 ’25.
